Lenacapavir (previously GS-6207) is the first in a new class of class HIV-1 capsid inhibitor that Gilead is hoping will eventually free patients from the need to take daily oral tablets, although ...

A solitary pulmonary nodule (SPN) is an isolated lung growth surrounded by normal tissue. Most SPNs are benign (not cancerous) when they're diagnosed. However, some nodules can enlarge and change over ...

Gilead Sciences has as of late been locked in on its bread-and-butter antiviral franchise with an eye on the potential of its long-acting HIV med lenacapavir. But with its cell therapy unit ...

Data from both studies showcased the superiority of twice-yearly injectable, lenacapavir, compared to once-daily oral Truvada and background HIV incidence rates, prompting Gilead to unblind the ...

Coleen F Kelly (Emory University, Atlanta, GA, USA) presented PURPOSE 2 evaluating safety and efficacy of twice-yearly subcutaneous lenacapavir for HIV prevention. 3271 cisgender gay men, bisexual men ...

A new study found that iron supplements are safe for children with HIV in Uganda, as they improve hemoglobin levels without increasing malaria risk. Iron supplements are safe for kids with HIV living ...

A recent study reveals that nearly 20% of United States physicians treating HIV patients plan to leave or reduce their caseload within five years, even as demand for HIV care is expected to rise.

Many innovative products are being introduced in China. Gilead Sciences submitted a market application to the Chinese authorities for its innovative HIV medicine lenacapavir, a twice-yearly injectable ...

Gilead Sciences is a biopharmaceutical company that discovers, develops, and commercializes innovative therapeutics in areas of unmet medical need. The company’s mission is to advance the care of ...